News & Publications

On April 6, 2021, Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, announced the extension of its original $12 million seed round to a total of $44 million.

In 2020, we served as counsel in more than 200 venture financings raising in excess of $10 billion, including some of the largest and most prominent deals of the year. Since 2010, we have handled approximately 2,700 venture financings with total proceeds in excess of $48 billion.

On February 24, 2021, Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, announced the successful closing of a $95 million Series C financing round.

On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing.

On January 7, 2021, Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, announced the completion of its $72 million Series B financing.

WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.

The 2020 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.

The 2020 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.

The 2020 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest for pre-IPO companies.

On Friday, March 27, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) became law.

In 2019, we served as counsel in more than 225 venture financings raising in excess of $5 billion, including some of the largest and most prominent deals of the year.

WilmerHale and 18 of its lawyers are once again recognized among the nation’s leading life sciences law firms and lawyers in the 2019 edition of LMG Life Sciences.

WilmerHale earned two Firm of the Year distinctions at the LMG Life Sciences Awards 2019.

LMG Life Sciences has named WilmerHale and six of its partners to its 2019 award shortlists in a total of 14 categories.

The 2019 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.